FDC or isomers: C0 > 5 % of Cmax [Regulatives / Guidelines]

posted by Achievwin – US, 2024-08-05 21:08 (688 d 05:52 ago) – Posting: # 24134
Views: 5,860

❝ The ICH’s M13A will soon supersed the FDA’s guidance. However, a similar procedure is stated in its Section 2.2.3.3 Carry over.


❝ The idea of assessing the predose concentrations in higher period(s) is to check whether the washout was sufficiently long. The treatment comparison in the presence of equal/unequal carryover would – unavoidably – be biased and there is no statistical method to adjust for it.


Oh my equal/unequal carryover – never ending story

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
122 visitors (0 registered, 122 guests [including 28 identified bots]).
Forum time: 03:01 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5